For the final piece in their series of articles for Cell & Gene, Walter Colasante, Pascale Diesel, and Lev Gerlovin address the new commercialization strategies being developed for gene and cell therapies. These new therapies offer great promise for patients and industry professionals alike, but with this promise comes with the potential to increase risk and cost, thus potentially limiting prospects for sustainable commercial success.
Some new best practices are beginning to emerge, such as a more flexible supply chain, precise patient targeting, and collaboration with the correct stakeholders. Additionally, companies that wish to successfully implement these therapies will need to rethink the structure of their go-to market models and identify and plan for the full range of commercial opportunities for their technology platforms. These new commercialization strategies give the industry the ability to optimize patient access and commercial opportunities associated with new gene and cell therapies.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Read the full piece here.
How to successfully commercialise microbiome-based diagnostics
In this Med-tech Innovation News article, Andrew Thomson, Brian Carpenter and Robert Broadnax explore key drivers of adoption of microbiome-based diagnostics,...